1. Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer
- Author
-
Xi Cheng, Yufei Yang, Ziliang Wang, Xin Chen, Midie Xu, Zihao Qi, Huizhen Sun, Haoran Li, Yong Wu, Hongyu Zhou, and Lingfang Xia
- Subjects
0301 basic medicine ,Vascular Endothelial Growth Factor A ,Cancer Research ,Angiogenesis ,B7-H1 Antigen ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,PD-L1 ,Medicine ,Animals ,Humans ,Apatinib ,PI3K/AKT/mTOR pathway ,Zebrafish ,RC254-282 ,Ovarian Neoplasms ,biology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Original Articles ,medicine.disease ,Vascular Endothelial Growth Factor Receptor-2 ,Ovarian Cancer ,Vascular endothelial growth factor ,030104 developmental biology ,VEGFR2 ,Oncology ,chemistry ,Tumor progression ,PD‐L1 ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,c‐JUN ,Female ,Original Article ,business ,Ovarian cancer - Abstract
Background Although programmed cell death‐ligand 1 (PD‐L1) plays a well‐known function in immune checkpoint response by interacting with programmed cell death‐1 (PD‐1), the cell‐intrinsic role of PD‐L1 in tumors is still unclear. Here, we explored the molecular regulatory mechanism of PD‐L1 in the progression and metastasis of ovarian cancer. Methods Immunohistochemistry of benign tissues and ovarian cancer samples was performed, followed by migration, invasion, and angiogenesis assays in PD‐L1‐knockdown ovarian cancer cells. Immunoprecipitation, mass spectrometry, and chromatin immunoprecipitation were conducted along with zebrafish and mouse experiments to explore the specific functions and mechanisms of PD‐L1 in ovarian cancer. Results Our results showed that PD‐L1 induced angiogenesis, which further promoted cell migration and invasion in vitro and in vivo of ovarian cancer. Mechanistically, PD‐L1 was identified to directly interact with vascular endothelial growth factor receptor‐2 (VEGFR2) and then activated the FAK/AKT pathway, which further induced angiogenesis and tumor progression, leading to poor prognosis of ovarian cancer patients. Meanwhile, PD‐L1 was found to be regulated by the oncogenic transcription factor c‐JUN at the transcriptional level, which enhanced the expression of PD‐L1 in ovarian cancer. Furthermore, we demonstrated that PD‐L1 inhibitor durvalumab, combined with the antiangiogenic drug, apatinib, could enhance the effect of anti‐angiogenesis and the inhibition of cell migration and invasion. Conclusion Our results demonstrated that PD‐L1 promoted the angiogenesis and metastasis of ovarian cancer by participating in the c‐JUN/VEGFR2 signaling axis, suggesting that the combination of PD‐L1 inhibitor and antiangiogenic drugs may be considered as a potential therapeutic approach for ovarian cancer patients., This manuscript demonstrated that PD‐L1 promoted the angiogenesis and metastasis of ovarian cancer by participating in the c‐JUN/VEGFR2 signaling axis, and suggested that the combination of PD‐L1 inhibitor and antiangiogenic drugs may be considered as a potential therapeutic approach for ovarian cancer patients.
- Published
- 2021